Global Hydrocephalus Research Report: Information by Type (Congenital Hydrocephalus, Acquired Hydrocephalus, Normal-Pressure Hydrocephalus, Ex-Vacuo Hydrocephalus), Diagnostic (CT scan – head, MRI, Head Ultrasound), Treatment (Surgery – Shunt Insertion, Ventriculostomy, Medication), End User (Hospitals & Clinics, Diagnostic Centres, Academic Institutions and Research Organizations) and Region - Forecast till 2023
ID: MRFR/MED/1187-CR | August 2019 | Region: Global | 139 pages
Market Scenario:
The Global Hydrocephalus Market is growing at a healthy pace and is expected to be USD 1,348.00 million in 2017, at a CAGR of 4.4% during the forecast period 2018-2023.
Hydrocephalus is a condition that characterized by buildup of cerebrospinal fluid (CSF) in the brain cavities (ventricles). The ventricles expand as a result of fluid accumulation, causing an abnormal increase in brain size. In normal conditions, the cerebrospinal fluid usually flows through the cavities of the brain and spinal column, but in hydrocephalus, the excessive CSF accumulation causes damage to the brain tissues, leading to a number of brain impairments. This condition can occur in any age, but it is more prevalent in infants and older adults. The increasing prevalence of hydrocephalus is directly responsible for the market growth. The major cause for this condition in children is found to be malnourishment of the fetus. this condition is mostly genetic however, it can also manifest in adults and is known as acquired hydrocephalus.
Shunting is a primary line of treatment for hydrocephalus. Shunting creates a bypass for the accumulated fluid to flow to other parts of the body. The increasing prevalence of traumatic brain injuries due to accidents and shifting patient preference towards minimally invasive surgeries in geriatric population are considered as the key factors that are projected to encourage the growth of the global hydrocephalus market in the coming years. In addition to this, the growing disposable income among consumers and the rapid development in the healthcare infrastructure are further predicted to enhance the growth of the overall market in the next few years.
Market Dynamics
The market for hydrocephalus is not very well developed due to lack of attention paid to the treatment of the disease. Following the development of shunts for draining the accumulated cerebrospinal fluid and scans to diagnose this condition, there have been improvements in terms of treatments to provide short-term relief to patients. However, there are efforts to develop treatments to address the disease at initial stages and this has ensured a positive growth trend for the market.
Further, Posttraumatic hydrocephalus (PTH) is a recurrent and serious complication that follows a traumatic brain injury (TBI). The prevalence of this condition varies greatly based on different criteria for its diagnosis. It can be caused by the blockage of normal cerebrospinal fluid (CSF) flow, overproduction of CSF, or insufficient absorption that result in excessive accumulation of CSF around the brain
The use of ICP devices is for measuring the fluid pressure within the brain which may be caused by trauma or other conditions. ICP monitoring has a significant importance in diagnostic and post-operative procedures with cranial injury as seen in cases of stroke, hydrocephalus, and trauma. According to the estimate of the Centers for Disease Control and Prevention (CDC) in 2017, more than 1.75 million traumatic brain injuries occur in North America, annually and these monitoring devices enable surgeons to save lives of patients with timely intervention and treatment. The increasing accidental cases causing traumatic brain injuries are going to act as drivers for the hydrocephalus market.
Figure 1: - Global Hydrocephalus Share, by Region 2017 (%)
Sources: WHO, Centers for Medicare & Medicaid Services, Annual Reports, Press Release, White Paper, and Company Presentation
Segmentation
The global Hydrocephalus market is segmented on the basis of type, diagnostic, treatment, end user. On the basis the type, the market is segmented into congenital hydrocephalus, acquired hydrocephalus, normal-pressure hydrocephalus, ex-vacuo hydrocephalus. on the basis of the diagnostic, the market is segmented into CT scan – head, MRI, head ultrasound. on the basis of treatment, it is segmented into surgery – shunt insertion, ventriculostomy, medication. on the basis of end user, it is segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations
Regional Analysis
The global market for hydrocephalus is segmented on the basis of regions into Americas, Europe, Asia Pacific, and Middle East & Africa.
The Americas held the largest share of the global hydrocephalus market owing to the rising prevalence of hydrocephalus, the presence of a well-developed healthcare sector, and the major market players. The continuous increase in the number of Americans affected from hydrocephalus coupled with ongoing research in neuroscience aid to the market growth. On a regional basis, the Americas is divided into North America and South America. North America is estimated to lead due to the presence of developed economies such as the US and Canada within the region. South America, however, is estimated to have the faster growth.
Europe stands second in the global market due to the constant evaluation of various techniques by neurosurgeons for the improvement of hydrocephalus management, is expected to drive growth in this market. Moreover, shunt manufacturers are engaged in investment for development of novel and improved shunts in order to tackle the pitfalls associated with the existing designs. The child population, aging in between 0 and 14 years, is estimated to increase from 17.6% of the total population in 2013 to 18.4% of the total population by 2020. This provides favorable background for market growth in Europe.
Key Players for the Global Hydrocephalus
Some of the key players in this market are DePuy Synthes, Boston Neurosciences, Medtronic Plc, Integra LifeSciences Corporation, Spiegelberg GmbH & Co. KG, RAUMEDIC Inc, Sophysa SA, Terumo Corporation, Natus Medical Incorporated, Johnson & Johnson Services Inc, B. Braun Melsungen AG, Christoph Miethke GmbH & Co. KG, Tokibo Co., Ltd, HLL Lifecare Limited and others
- September 2017 Natus Medical Incorporated acquired neurosurgery business assets from Integra LifeSciences, thus entering into the neurosurgery business segment
- October 2017 Integra Lifesciences acquired Codman Neuro from Johnson & Johnson for USD 1.1 billion. Integra is divesting its assets in order to get FTC's permission on its proposed acquisition of Johnson & Johnson's Codman Neurosurgery business. The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neurointensive care, and cranial surgery, and generated net revenues of approximately USD 371.5 million in 2016.
Market Segmentation
Global Hydrocephalus, by Type
- Congenital hydrocephalus
- Acquired hydrocephalus
- Normal-pressure hydrocephalus
- Ex-vacuo hydrocephalus
Global Hydrocephalus, by Diagnostic
- CT scan – head
- MRI
- Head Ultrasound
Global Hydrocephalus, by Treatment
- Surgery – Shunt Insertion
- Ventriculostomy
- Medication
Global Hydrocephalus, by End User
- Hospitals & Clinics
- Diagnostic Centres
- Academic Institutions and Research Organizations
Intended Audience
- Pharmaceutical Companies
- Hospitals
- Research and Development (R&D) Companies/Laboratories
- Market Research and Consulting Service Providers
- Potential Investors
Frequently Asked Questions (FAQ) :
The hydrocephalus market valuation was USD 1348 million in 2017.
The projected CAGR would be 4.4% for the forecast period.
The end users are diagnostic centers, hospitals & clinics, academic institutions & research organizations.
The segments are MRI, CT scan – head, and head ultrasound.
America is leading the hydrocephalus market.
Global Hydrocephalus Market - Summary
Overview
Hydrocephalus is medical condition in which excess levels of cerebrospinal fluid (CSF) in the ventricles can increase the intracranial pressure in the brain. This condition in noticeable in infants and older adults. Infants are likely to attain this disorder either due to genetics or malnourishment in the fetal stage.
The global hydrocephalus market is expected to reach a valuation of USD 1,752.07 million by 2023 at a CAGR of 4.4% from 2018 to 2023 (forecast period). The exponential growth is credited to increasing incidence of traumatic brain injuries (TBI). According to the Centers for Disease Control & Prevention (CDC), nearly 1.75 million cases of TBI occurred in 2017. Continuous development of shunts and other equipment for increasing the success of hydrocephalus surgeries is likely to boost market demand.
Favorable medical reimbursement schemes which cover treatment costs can provide the hydrocephalus market the required tailwind. This is backed by inflated healthcare expenditure of nations in the Gulf Cooperation Council (GCC) and others. High prevalence of neurological conditions such as brain aneurysm can further the market growth as well. According to the Brain Aneurysm Foundation, the condition has been responsible for causing 500,000 deaths worldwide annually. Moreover, medical reimbursement schemes covering brain aneurysm treatment such as stents can bode well for the market.
Industry Opportunities
Intraoperative neurophysiological monitoring (IONM) are an array of methods designed to check the functions of nerves during surgery. Emergence of medical institutions which are offering courses to medical professionals for upskilling is likely to bode well for the market. In addition, technological breakthroughs in the form of endovascular embolization and wire micro-guide catheters which can provide a pathway to the brain. Both procedures offer good outcomes with low amount of medical complications.
Segmentation
Types include acquired hydrocephalus, congenital hydrocephalus, ex-vacuo hydrocephalus, and normal-pressure hydrocephalus (NPH). Congenital hydrocephalus dominated the hydrocephalus market in 2017 owing to the condition being prevalent in neonates. It can exhibit a strong growth rate over the forecast period due to efforts by nations to lower the mortality rate caused by the neurological condition. But the NPH segment is expected to exhibit an impressive CAGR owing to its high prevalence in patients above the age of 60.
Methods of diagnosis for the medical condition in the hydrocephalus market include MRI, head ultrasound, and CT scan-head. MRI remains the most trustworthy method and will exhibit the highest CAGR in the market till 2023. The technology can scan accurate images of the brain to discern the presence of malformations. This can be used to detect hydrocephalus and other neurological or neurovascular conditions.
By treatment, the market is segmented into medication, ventriculostomy, and surgery-shunt insertion. The surgery-shunt insertion segment can exhibit an impressive CAGR during the forecast period owing to the improvement shown in draining the excess levels of CSF. Ventriculostomy can display an impressive growth rate owing to extensive application of ventricle shunts used for creating a path for CSF to exit.
End-users in the hydrocephalus market include hospitals & clinics, research institutes & academic centers, and diagnostic centers. Hospitals & clinics can generate significant revenue for the market owing to the institution equipped with intracranial pressure (ICP) monitors. High prevalence of TBI being treated by surgeons at hospitals with high success outcomes can augur well for the segment. But diagnostic centers can display the strongest growth rate owing to the need for high-resolution procedures to detect abnormalities in brain ventricles at an early stage.
Regional Analysis
Geographic segmentation of the hydrocephalus market comprises Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas held the highest market share in 2017 owing to high prevalence of neurological conditions, sophisticated healthcare infrastructure, and presence of major players. On the other hand, APAC can display the highest growth rate owing to rapid growth of China and India and their large patient pool. Government support in form of funding to expedite research and development in shunts and other imaging technologies can drive the regional hydrocephalus market till 2023.
Competitive Landscape
Key players in the hydrocephalus market include HLL Lifecare Limited (India), Integra LifeSciences Corporation (U.S.), Johnson & Johnson Services Inc. (U.S.), Natus Medical Incorporated (U.S.), B. Braun Melsungen AG (Germany), Boston Neurosciences (U.S.), Terumo Corporation (U.S.), Medtronic Plc (Ireland), Spiegelberg GmbH & Co. KG (Germany), Sophysa SA (France), RAUMEDIC Inc. (Germany), DePuy Synthes (U.S.), Christoph Miethke GmbH & Co. KG (Germany), and Tokibo Co., Ltd. (Japan).
TABLE OF CONTENT
Global Hydrocephalus Market: Competitive Landscape
The prominent players in the global hydrocephalus market are Medtronic Plc (PS Medical), Codman (Johnson & Johnson), Integra LifeSciences Corporation, B. Braun Melsungen AG, DePuy Synthes, Christoph Miethke GmbH & Co. KG, Spiegelberg GmbH & Co. KG and others.
Medtronic Plc (PS Medical) is the holds the largest share for the global hydrocephalus market in 2017. The company is a global healthcare solutions company committed to improving the lives of people through medical technologies, services, and solutions. Medtronic Plc with Covidien has accelerated and advanced its ability to create meaningful innovations for hospitals, health systems, and healthcare providers so that it can deliver the best care possible to patients and their families around the world.
Codman (Johnson & Johnson) holds second position in terms of market share in the global hydrocephalus market in 2017. The company manufactures medical devices for various specialties, such as orthopedics, cardiovascular diseases, and many others. J&J Services has acquired and merged with various other companies to expand its portfolio of endoscopic devices. Ethicon, a subsidiary of J&J offers a broad range of suture needle products
Integra LifeSciences Corporation holds third position in terms of market share in the global hydrocephalus market in 2017. The company is an international leader in medical technology. The key focus of the company is to provide patients with a high level of satisfaction. The company also provides and operates innovative solutions in the field of orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. In the US, Integra LifeSciences Corporation is one of the leading players for providing surgical devices and instruments to various hospitals, surgery centers, physicians, and dental offices.
- Braun Melsungen AG is a leading healthcare supplier. The company provides its products for hospitals, surgeries, private practices (medical care and doctors´ offices), and extracorporeal blood treatments. The company’s product segments include clinical nutrition, urinary care, infection prevention, infusion therapy, diabetes care, neurosurgery, extracorporeal blood treatment, IV drugs, orthopedics, spine, and wound care, among others. The company operates in four major divisions, namely, hospital care, Aesculap, outpatient market, and B. Braun Avitum. With these four divisions, the company has a wide range of products with about 5,000 products, out of which 95% of the products are manufactured by the company. Geographically the company operates in 64 countries in regions such as Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
DePuy Synthes is a contract manufacturing organization of softgel capsules and supplies to the nutritional supplement market. It operates a Good Manufacturing Practices (GMP) facility licensed by the UK Medicines & Healthcare products Regulatory Authority (MHRA). EuroCaps is a part of DCC Health and Beauty Solutions, a subsidiary of DCC Healthcare.
Medtronic Plc (PS Medical), and Codman (Johnson & Johnson) are the major companies for hydrocephalus operating on a global scale. The lower market share of Spiegelberg GmbH & Co. KG can be attributed to fewer products offering, as compared to other major players. Key players such as Christoph Miethke GmbH & Co. KG, RAUMEDIC Inc., Natus Medical Incorporated, Terumo Corporation, Boston Neurosciences increase the level of competition in the global hydrocephalus market, as these companies are expected to expand their product portfolios, with the help of other business units, to increase their market share.
